

REMARKS/ ARGUMENTS

Claims 1, 3 and 16-26 are pending in the current application. Claim 2, 4-15 and 27-28 have been cancelled. Applicant expressly reserves the right to file continuing applications to the cancelled subject matter. Applicant addresses each of the rejections below, in the order in which they are presented in the Office Action.

Claim Rejections Have Been Addressed

35 U.S.C. 103(a)

Claims 2 and 5 to 15 were rejected under 35 U.S.C. 103(a) as being unpatentable over Anderson et al (5,471,001). Applicant respectfully submits that this rejection is moot in light of the claim amendments and requests that it be withdrawn.

Claims 4, 27 and 28 were rejected under 35 U.S.C. 103(a) as being unpatentable over Anderson et al (5,471,001) in view of Al-Ghazawi et al (2003/0203937). Applicant respectfully submits that this rejection is moot in light of the claim amendments and requests that it be withdrawn.

It is respectfully submitted that the present application is in condition for allowance.

Should any outstanding issues remain, the Examiner is encouraged to contact Applicant's undersigned representative.

Respectfully submitted:

Date: Oct 18, 2007

Customer No. 23347

GlaxoSmithKline

Corporate Intellectual Property

Five Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-1891

Facsimile: (919) 483-7988

By: Alice P. Bradney
Alice P. Bradney
Attorney of Record
Registration No. 51,491